0.67
price up icon2.01%   0.0132
pre-market  Pre-market:  .67  
loading
Jupiter Neurosciences Inc stock is traded at $0.67, with a volume of 58,165. It is up +2.01% in the last 24 hours and down -7.87% over the past month. Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
See More
Previous Close:
$0.6568
Open:
$0.6813
24h Volume:
58,165
Relative Volume:
0.11
Market Cap:
$20.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.5964
EPS:
-0.0882
Net Cash Flow:
-
1W Performance:
+8.06%
1M Performance:
-7.87%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$0.6312
$0.6987
1-Week Range:
Value
$0.5889
$0.6987
52-Week Range:
Value
$0.51
$19.51

Jupiter Neurosciences Inc Stock (JUNS) Company Profile

Name
Name
Jupiter Neurosciences Inc
Name
Phone
(561) 406-6154
Name
Address
1001 NORTH US HWY 1, JUPITER
Name
Employee
4
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
JUNS's Discussions on Twitter

Compare JUNS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
JUNS
Jupiter Neurosciences Inc
0.67 20.54M 0 0 0 -0.0882
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Jupiter Neurosciences Inc Stock (JUNS) Latest News

pulisher
Apr 21, 2025

Jupiter Neurosciences appoints new auditor amid transition - Investing.com Australia

Apr 21, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences targets Parkinson’s and longevity markets By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences targets Parkinson's and longevity markets - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant - Stock Titan

Apr 08, 2025
pulisher
Mar 28, 2025

Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 26, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com

Mar 25, 2025
pulisher
Mar 18, 2025

Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma

Mar 18, 2025
pulisher
Mar 07, 2025

Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph

Mar 07, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products - Yahoo Finance

Mar 04, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria

Feb 10, 2025
pulisher
Feb 07, 2025

Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing

Feb 07, 2025
pulisher
Feb 07, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN

Feb 07, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView

Feb 04, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa

Feb 03, 2025
pulisher
Feb 03, 2025

Clinical Trials News Live Feed - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today

Feb 03, 2025
pulisher
Jan 31, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India

Jan 31, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa

Jan 30, 2025
pulisher
Jan 24, 2025

Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView

Jan 24, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India

Jan 24, 2025
pulisher
Jan 23, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com

Jan 23, 2025
pulisher
Jan 23, 2025

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK

Jan 23, 2025
pulisher
Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights

Jan 23, 2025
pulisher
Jan 22, 2025

Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn

Jan 22, 2025
pulisher
Jan 22, 2025

Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn

Jan 22, 2025
pulisher
Jan 21, 2025

Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail

Jan 21, 2025
pulisher
Jan 14, 2025

Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online

Jan 14, 2025

Jupiter Neurosciences Inc Stock (JUNS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):